ArticlePlanta2026
Development of a high-performance synthetic promoter for plant-based bioproduction.
Article in Planta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Genome editing‑based strategies to combat geminiviruses: CRISPR/Cas9 and emerging high‑fidelity tools.Archives of microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MAIN
conclusionThe study developed a synthetic FM promoter through domain shuffling of pararetroviral promoters, achieving 4-fold higher activity than CaMV35S in plants. It enhanced recombinant protein yields, demonstrated by effective scytovirin production against Chikungunya, proving FM's utility in plant synthetic biology and molecular farming. Plant synthetic biology requires high-performance constitutive promoters to maximise recombinant protein yields. In this study, we developed a synthetic promoter (FM) through strategic intermolecular domain shuffling of key regulatory regions derived from the full-length transcript promoters of Figwort mosaic virus (FMV) and Mirabilis mosaic virus (MMV). Functional characterization in transient systems demonstrated that this promoter drives exceptionally strong expression of reporter genes across three model plant species: Nicotiana tabacum, Nicotiana benthamiana, and Petunia × atkinsiana. Quantitative β-glucuronidase (GUS) assays revealed that the FM promoter exhibits 4.0-fold higher activity than the conventional CaMV35S promoter in tobacco, and also outperformed the modified CaMV35S2 promoter by 2.0-fold. These results were further validated in stable transgenic lines of N. tabacum and A. thaliana, where qRT-PCR and histochemical staining consistently showed superior transgene expression relative to CaMV35S controls. Through systematic mutagenesis analysis of the FM promoter, we identified that the as-1, G-Box, and ABRE cis-elements are critical for its high activity. We further demonstrated the promoter's compatibility with orthogonal regulation systems by enhancing FM-driven expression using CRISPR-dCas9/VP64 synthetic transcriptional activation. To evaluate biotechnological applications, an antiviral peptide scytovirin (SVN) was expressed under the control of the FM promoter in transgenic N. tabacum plants. In vitro antiviral assays against Chikungunya virus (CHIKV) confirmed that the plant-produced SVN retained biological activity and significantly reduced viral titers by 60%. These results collectively demonstrate the FM as a compact, high-performance synthetic promoter, making it especially valuable for plant molecular farming.
Indexed as
Identifiers
41553553What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.